The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Footsie finishes flat after long weekend

Tue, 28th Aug 2012 16:48

- Markets await Jackson Hole symposium- Miners lower on concerns over Japan- Chemring drops after profit warning. Concerns about global economic growth were weighing on sentiment on Tuesday, meaning that the FTSE 100 was little changed by the close despite some volatile swings between gains and losses throughout the session.Meanwhile, speculation about quantitative easing (QE) measures from the US Federal Reserve was continuing to do the rounds. Market strategist Brenda Kelly from CMC Markets said: "The almost absolute certainty displayed in recent price action that the Fed would ease at Jackson Hole this weekend seems to have petered out, with the major European indices pulling back further from their recent highs and entering a consolidative mode." The Japanese government reduced its assessment of the economy today, warning that a slowdown in economic growth overseas and the ongoing Eurozone debt crisis are key risks to the world's third-largest economy. JPMorgan Securities Japan and BNP Paribas are forecasting a 0.3% and 0.9% decline in third-quarter Japanese gross domestic product (GDP), respectively. Japan's concerns about economic growth overseas will likely have been exacerbated after the release of some gloomy figures from China and Spain. It was a revealed yesterday that combined profits in the industrial sector in China, a major trade partner to Japan, dropped by a year-on-year rate of 5.4% in July, worse than the 1.7% decline seen the month before.Meanwhile, Spanish GDP declined at a 1.3% annual rate in the second quarter, compared with the initial estimate of a 1% contraction, the country's national statistics office said. News that the Generalitat of Catalonia will request €5.023bn from the Spanish government's liquidity fund spooked markets today, dampening earlier optimism after a successful short-term bond auction which saw borrowing costs drop and demand improve.FTSE 100: Miners drop on Japanese concerns; G4S falls after first-half results Miners were firmly out of favour today on concerns over the Japanese economy. BHP Billiton fell after announcing the sale of its Yeelirrie uranium deposit in Western Australia to Cameco for $430m. BHP and sector peers ENRC, Kazakhmys and Vedanta were also lower after Morgan Stanley reduced its target price for all four stocks. Security giant G4S fell after expressing disappointment over the problems related to its Olympics contract, saying that it will incur a £50m loss on the contract in the first half. Meanwhile, the company said that a review of its overhead structure will lead the loss of 1,100 jobs. Nevertheless, the firm revealed that turnover at constant exchange rates rose 7.5% while profits were flat. Retail peers M&S and Kingfisher were both lower this afternoon. M&S was pulling back after a sharp rise on Friday after rumours that private equity titan CVC Capital Partners is considering a takeover offer. Meanwhile, B&Q owner Kingfisher was lower after Bank of America Merrill Lynch lowered its rating to 'underperform'. Drugs giant AstraZeneca was lower after saying that it has appointed Roche's Chief Operating Officer as its new Chief Executive Officer. Meanwhile, the firm also announced that the European Commission has granted marketing authorisation to its ZINFORO treatment. Sector peer GlaxoSmithKline was suffering from a downgrade by UBS. Bunzl, the international distribution and outsourcing group, fell despite saying that pre-tax profits and revenues in the first half rose 9% and 7%, respectively. Telecoms group BT rose after Credit Suisse reiterated its 'outperform' rating and saying that it expects BT, along with BSkyB to take broadband market share.FTSE 250: Chemring drops after profit warning Defence contractor Chemring dropped after it issued a profits warning, saying a computer glitch and production delays are likely to wipe £15m off full-year earnings as it considers a takeover offer from private equity giant Carlyle. Heading the other way was chemicals group Yule Catto after reporting a pre-tax profit of £56m in the first half, up from £52.4m the year before. Sales, however, fell to £603.3m from £664.3m. FTSE 100 - RisersGlencore International (GLEN) 384.00p +4.67%Carnival (CCL) 2,170.00p +3.73%International Consolidated Airlines Group SA (CDI) (IAG) 144.90p +2.48%BT Group (BT.A) 219.50p +2.00%Capital Shopping Centres Group (CSCG) 334.60p +1.73%Xstrata (XTA) 939.20p +1.24%ITV (ITV) 84.40p +1.02%Barclays (BARC) 188.95p +0.93%Ashmore Group (ASHM) 334.20p +0.81%CRH (CRH) 1,140.00p +0.80%FTSE 100 - FallersEurasian Natural Resources Corp. (ENRC) 318.60p -5.99%Evraz (EVR) 233.90p -5.23%Kazakhmys (KAZ) 634.00p -4.01%Kingfisher (KGF) 276.00p -3.40%Marks & Spencer Group (MKS) 362.80p -2.39%Vedanta Resources (VED) 904.00p -2.22%G4S (GFS) 261.00p -1.95%Rio Tinto (RIO) 2,862.00p -1.65%Intertek Group (ITRK) 2,715.00p -1.52%IMI (IMI) 844.50p -1.46%FTSE 250 - RisersYule Catto & Co (YULC) 158.00p +11.42%Moneysupermarket.com Group (MONY) 139.20p +6.26%Ted Baker (TED) 1,017.00p +5.17%Imagination Technologies Group (IMG) 595.00p +5.03%Centamin (DI) (CEY) 79.10p +3.87%Renishaw (RSW) 1,573.00p +2.88%Menzies(John) (MNZS) 620.00p +2.73%Carpetright (CPR) 640.00p +2.32%Dialight (DIA) 1,097.00p +2.14%Britvic (BVIC) 315.00p +1.65%FTSE 250 - FallersChemring Group (CHG) 324.00p -12.55%BTG (BTG) 300.30p -5.77%Cairn Energy (CNE) 283.70p -4.25%Bumi (BUMI) 340.00p -4.23%Afren (AFR) 124.70p -4.00%EnQuest (ENQ) 111.90p -2.86%Ophir Energy (OPHR) 531.00p -2.84%Man Group (EMG) 73.60p -2.84%Cape (CIU) 187.70p -2.80%Hunting (HTG) 771.50p -2.77%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.